Registry Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain NeoplasmsContinue reading
Category Archives: AZBio News
KOL Conversation: The Impact of the IRA on Oncology Patient Care
Impact of the IRA on Oncology Patient Care features an interview with Dr. Barbara L. McAneny, MD, FASCO, MACP Former President for the American Medical Association and the New Mexico Medical Society (NMMS); and currently CEO, New Mexico Cancer Center.
With Dr. Steve Potts CEO, Anticipate Bioscience.
Impact of the IRA on Oncology Patient Care was recorded on the 26th of May 2023Continue reading
Connect with Arizonans at RESI and BIO2023 in Boston
Arizona Health Innovators are headed to Boston for RESI and the BIO International Convention June 5 - 8. 2023.
Anuncia Medical Inc. Announces Published Data with Promising Clinical Outcomes Using the ReFlow™ Ventricular System In-Line with Hydrocephalus Shunts
SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ — Anuncia Medical Inc. (“Anuncia” or the “Company”), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce that an article highlighting its FDA cleared and CE Marked ReFlow™ Ventricular System “Gen 1” with Hydrocephalus shunts in patients suffering from chronic shunt occlusions, has been published in Pediatric Neurosurgery. Two years prior to being implanted with the ReFlow™ System, 7 of the 9 patients represented in the publication experienced a combined total of 14 proximal shunt failures that required revision. In the 2-4 years following ReFlow™ implantation and use to maintain flow, only 1 proximal shunt failure occurred amongst the 9 patients. As revisions are typically associated with expensive hospital admissions for both the child and family, reducing the number of revisions needed is invaluable to those impacted.Continue reading
Atlanta Nonprofit, Purple Pansies, Donates $726,000 in Support of TGen Clinical Study
PHOENIX, ARIZONA — MAY 23, 2023 — A $726,000 donation from Atlanta-based charity Purple Pansies will support a TGen-led clinical trial designed to increase a patient’s unfolded protein response (UPR) to push the cancer cells to reach a state of programmed cell death. UPR is a cellular defense mechanism that, when triggered, sends signals to the cell’s nucleus to restore balance and ensure that proteins are folded properly, which is essential for normal cell function.Continue reading
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
Leading Neuro-Oncologist Yoshie Umemura, MD, Joins Barrow Neurological InstituteContinue reading
AZAdvances Talent Receives Grant to Support STEM Workforce Opportunities
Senator Sinema lauds efforts to further fund growing internship program for Arizona studentsContinue reading
Xcellerant and Flinn Foundation Partner to Fuel Growth in Arizona Bioscience and Healthcare Sectors
SCOTTSDALE, Ariz–(BUSINESS WIRE)–Xcellerant Ventures (XVC) welcomes the Flinn Foundation as a limited partner in its Xcellerant Venture Capital Fund I. Xcellerant Ventures is a venture capital firm investing in early and seed stage startups within the HealthTech and MedTech sectors. Xcellerant seeks to invest in dynamic founding teams with strong intellectual property portfolios that XVC believes will transform medical practice and dramatically improve healthcare.
A century later, HonorHealth Research Institute examines first potentially effective treatment for Lou Gehrig’s Disease
HonorHealth Research Institute is one of just 30 sites worldwide participating in this first ALS prevention study, sponsored by Biogen. The focus of the study is to identify individuals who are genetically predisposed to acquiring ALS, specifically those who carry the SOD1 gene but who don’t yet show any symptoms.Continue reading
GT Medical Technologies Marks a Significant Milestone: The 1,000th Order for GammaTile® Therapy
TEMPE, Ariz., May 18, 2023 /PRNewswire/ — GT Medical Technologies, Inc. announced receipt of the 1,000th order for GammaTile Therapy.
Driven to overcome the limitations of current treatments for brain tumors and improve the standard of care, a team of brain tumor specialists joined forces to form GT Medical Technologies, Inc. GammaTile Surgically Targeted Radiation Therapy (STaRT) is the newest option for patients undergoing brain tumor resection. Continue reading